NDC properties for "Tascenso 0.5 MG Disintegrating Oral Tablet" (RxCUI 2626385)
About this data
The tables show NDC propoerties for Tascenso 0.5 MG Disintegrating Oral Tablet with the RxCUI 2626385
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for Tascenso 0.5 MG Disintegrating Oral Tablet (RxCUI 2626385)
| MMSL_CODE | BD39230 |
|---|---|
| NDA | NDA214962 |
| RxCUI | 2626385 |
| SPL_SET_ID | bf8e7f89-ea09-43c7-a7eb-e44724350721 |
| Prescribable Synonym | Tascenso ODT 0.5 MG Disintegrating Oral Tablet |
| RXNAV_STR | Tascenso 0.5 MG Disintegrating Oral Tablet |
| RxNorm Name | fingolimod 0.5 MG Disintegrating Oral Tablet [Tascenso] |
| RxNorm Synonym | Tascenso 0.5 MG Disintegrating Oral Tablet |
| Related queries | Interactions (for RxCUI 2626385) |
NDC Properties
NDC Item 70709006530
| NDC 9 | 70709-065 |
|---|---|
| NDC 10 | 70709-065-30 |
| NDC Item | 70709006530 |
| Packaging | 3 BLISTER PACK in 1 CARTON (70709-065-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
| COLORTEXT | WHITE(White to off-white) |
| Color | C48325 __ |
| FDA SPL set id | 866931 |
| Labeler | Cycle Pharmaceuticals Ltd |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time low | 2023-02-01 |
| Marketing status | ACTIVE |
| NDA | NDA214962 |
| Score | 1 |
| Shape | C48348 |
| Size | 16 mm |
| Related queries | Properties for NDC 9 70709-065 |